EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency

Application is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated non-small cell lung cancer.